COMP <GO>
CYTK vs TGTX // FREE CASH FLOW YIELD
Cytokinetics Incorporated (NASDAQ) VS. TG Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CYTK 1
— TGTX 9
▲ FREE CASH FLOW YIELD LEADER: TGTX
LAST: $62.03 (-1.52%) • MKT CAP: $8.76B
fcf-yield
-6.08%
LAST: $59.95 (-2.01%) • MKT CAP: $9.36B
fcf-yield
-0.28%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CYTK VS. TGTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CYTK | TGTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 83.70% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.00% | -47.00 | TGTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 73.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -6.08% | -0.28% | -5.80 | TGTX | /fcf-yield <GO> |
| Operating Margin | -60.00% | 20.00% | -80.00 | TGTX | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 68.00% | -128.00 | TGTX | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 87.30% | +92.70 | CYTK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.45 | 12.92 | -12.47 | TGTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 6/9 | -1.00 | TGTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.0 | 64.7 | -18.70 | TGTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.87 | 0.87 | 0.00 | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 31.0x | 16.7x | +14.30 | TGTX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $8.76B | $9.36B | -$607.7M | TGTX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CYTK REV | TGTX REV | CYTK GROSS % | TGTX GROSS % | CYTK FCF | TGTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $88.0M | $616.3M | — | 83.7% | -$534.8M | -$25.0M |
| FY 2024 | $18.5M | $329.0M | — | 88.3% | -$399.8M | -$40.6M |
| FY 2023 | $7.5M | $233.7M | — | — | -$414.7M | -$41.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CYTK // BETA 0.87
TGTX // BETA 0.87